- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 239/20 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
Patent holdings for IPC class C07D 239/20
Total number of patents in this class: 57
10-year publication summary
|
3
|
6
|
8
|
4
|
2
|
4
|
2
|
5
|
4
|
0
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| VALO Health, Inc. | 193 |
5 |
| Enanta Pharmaceuticals, Inc. | 427 |
4 |
| Bristol-myers Squibb Company | 4756 |
3 |
| Takeda Pharmaceutical Company Limited | 2704 |
3 |
| Paratek Pharmaceuticals, Inc. | 104 |
3 |
| Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China | 173 |
2 |
| Universite de Montreal | 345 |
2 |
| The Walter and Eliza Hall Institute of Medical Research | 160 |
2 |
| Certest Biotec, S.L. | 40 |
2 |
| Janssen Sciences Ireland Unlimited Company | 381 |
2 |
| Merck Sharp & Dohme LLC | 3723 |
2 |
| Beactica Therapeutics AB | 2 |
2 |
| BASF SE | 21339 |
1 |
| Merck Sharp & Dohme Corp. | 2183 |
1 |
| Commissariat à l'énergie atomique et aux energies alternatives | 11137 |
1 |
| Astex Therapeutics Limited | 200 |
1 |
| Cristalia Produtos Quimicos Farmaceuticos Ltda. | 24 |
1 |
| Doosan Corporation | 432 |
1 |
| Epizyme, Inc. | 360 |
1 |
| Fochon Pharma, Inc. | 1 |
1 |
| Other owners | 17 |